We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Equivocal HbA1c Test Results Increases Risk of Neonatal Hypoglycemia

By LabMedica International staff writers
Posted on 10 Sep 2020
Print article
Image: Impact of maternal HbA1c levels ≤ 6% and race in non-diabetic pregnancies on birth weight and early neonatal hypoglycemia (Photo courtesy of Diabetes Self-Management).
Image: Impact of maternal HbA1c levels ≤ 6% and race in non-diabetic pregnancies on birth weight and early neonatal hypoglycemia (Photo courtesy of Diabetes Self-Management).
Maternal diabetes, including gestational diabetes, typically diagnosed by an oral glucose tolerance test in the second trimester, is a known risk factor for neonatal hypoglycemia and infants born large for gestational age.

Clinicians have suspected that some infants born to mothers without overt diabetes or gestational diabetes may still have an increased risk for hypoglycemia and tend to be larger at birth. However, this has not been systematically evaluated during pregnancy, especially in the context of long-term glucose control in pregnant women.

Pediatricians at the Hurley Children’s Hospital (Flint, MI, USA) and their colleagues analyzed data from 4,769 infants born at 34 weeks’ gestation or later at Hurley Medical Center from 2015 to April 2018, including 21,482 blood glucose measurements. The mean gestational age at delivery, 37.3 weeks; 63% were delivered vaginally; 54% were white; 50% male neonates). Glycated hemoglobin (HbA1c) values were available for 4,391 mothers with 6,312 measurements during pregnancy. Mothers and infants were stratified into four groups: mothers without documented pregnancy conditions; prenatal exposure to beta-blockers; prenatal exposure to diabetes; or prenatal exposure to beta-blockers and diabetes.

The team noted that within the cohort, 4.9% of infants were born large for gestational age. Among infants born to mothers with no documented pregnancy conditions, they observed a statistically significant relationship between pregnancy HbA1c level and birth weight for white and black infants. They found that, overall, third trimester HbA1c was higher among mothers whose infants had hypoglycemia versus. mothers whose infants did not have hypoglycemia (mean, 5.3% versus 5.1%); with the trend manifesting at a lower HbA1c level for infants born to white mothers (mean HbA1c, 5.2%) versus black mothers (mean HbA1c, 5.4%).

Among infants born to white mothers, increases in HbA1c levels from 4.8% to 6% increased the risk for hypoglycemia from 25% to 48% in late preterm, and from 12% to 22% in term deliveries. Among infants born to black mothers, the same maternal HbA1c range increased hypoglycemia risk from 15% to 26% in late preterm and from 5% to 10% in deliveries. Additionally, each 0.1% increase in HbA1c levels between 4.8% and 6% increased the odds of neonatal hypoglycemia by 6.4% among blank infants and by 12% among white infants.

Venkatesh Sampath, MD, MRCPCh, a Professor of Pediatrics and the senior author of the study, said, “For clinicians, these findings, if confirmed in prospective study, can help identify at-risk infant populations who would need closer monitoring to prevent early neonatal hypoglycemia. Clinicians may consider routine screening of HbA1c of mothers and incorporate such testing into clinical practice. Such measure may decrease the incidence of hypoglycemia potentially, a common clinical problem in the neonate.”

The authors concluded that Pregnancy HbA1c levels between 4.8%-6.0% considered acceptable during pregnancy impacts neonatal hypoglycemia and birth weight especially in Caucasian race. A third trimester HbA1c greater than 5.2% is a potential risk factor for neonatal hypoglycemia, especially in preterm infants. The study was published on August 12, 2020 in The Journal of Pediatrics.

Related Links:
Hurley Children’s Hospital

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.